“The cfi in glaxo collapses the concepts of object and effect. this is contrary to the existing case law and is disastrous for the commission.” discuss.
The case started when Glaxo, under the old system of notification procedure , notified the Commission of its ‘General sales conditions of pharmaceutical specialities to authorised wholesalers’. The contract introduced dual pricing for pharmaceuticals sold in Spain with the aim to prevent parallel exports to the UK where the same products were sold more expensively. Glaxo argued that in order to invest money into the development of new drugs, it needed to retain the profits from the parallel trade, as in the pharmaceuticals industry the real competition is not in price but in innovation.The Commission´s findings – that there was restriction by object and the infringement under Article 81(1) was not eligible for an exemption under Article 81(3) – resulted in Glaxo challenging the decision before the Court of First Instance (CFI).
The CFI found that the agreement was a restriction by effect and ordered the Commission